Bronze
NGeneBio was founded in 2015 as a spin-off venturefrom Korea Telecom (KT), develops in vitro diagnostics (IVD)/companiondiagnostics (CDx) products and bioinformatics SW with cutting-of-edgetechnologies including next generation sequencing (NGS). The company launchedNGS-based breast/ovarian cancer NGS panel (BRCAaccuTest™) withclinical analysis SW (NGeneAnalySys™) and received CE-IVD and KFDA approval in 2017. Additionally launchedNGS panels and SW for solid tumor (SOLIDaccuTest™) and hematological malignancies (HEMEaccuTest™, CE-IVD marked in 2018). Short Tandem Repeat(STR) kits, IDaccuTest™,compatible with Sanger sequencer for chimerism genetic testing aftertransplantation were also launched.
HEMEaccuTest™ makes it possible to analyze the major gene mutation patterns of patients having malignant tumors occurred in blood, blood vessels, lymph nodes, lymphatic organs, and constitute a variety of gene instability such as gene mutation, rearrangement, and amplification and to enable personalized diagnosis using NGS technology. It provides data QC, analysis and automated variant information by using optimized analysis software (NGeneAnalySys™) for hematological malignancies panel. HEMEaccuTest™ received CE-IVD mark in 2018.